Leerink Partnrs Has Negative Outlook of BMRN Q1 Earnings

Key Points

• Leerink Partners has lowered its Q1 2026 earnings per share estimate for BioMarin Pharmaceutical from $0.92 to $0.86, while the full-year estimate remains at $3.15 per share.
• BioMarin Pharmaceutical currently holds an average rating of "Moderate Buy" with a target price of $93.26, reflecting a mix of ratings from different analysts.
• More than 98% of BioMarin's stock is owned by institutional investors, indicating strong institutional interest in the company.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Equities research analysts at Leerink Partnrs cut their Q1 2026 EPS estimates for shares of BioMarin Pharmaceutical in a research report issued to clients and investors on Wednesday, October 8th. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will post earnings of $0.86 per share for the quarter, down from their previous estimate of $0.92. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $3.15 per share. Leerink Partnrs also issued estimates for BioMarin Pharmaceutical's Q2 2026 earnings at $0.89 EPS.

Several other brokerages also recently issued reports on BMRN. Wedbush reissued an "outperform" rating and set a $94.00 price objective on shares of BioMarin Pharmaceutical in a research note on Tuesday, August 5th. Weiss Ratings reissued a "sell (d+)" rating on shares of BioMarin Pharmaceutical in a research note on Wednesday. Zacks Research cut BioMarin Pharmaceutical from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th. JPMorgan Chase & Co. lifted their price objective on BioMarin Pharmaceutical from $116.00 to $119.00 and gave the company an "overweight" rating in a research report on Thursday. Finally, UBS Group increased their target price on BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a "buy" rating in a research report on Tuesday, August 5th. Thirteen investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, BioMarin Pharmaceutical currently has an average rating of "Moderate Buy" and an average target price of $93.26.

BioMarin Pharmaceutical Price Performance

BioMarin Pharmaceutical stock opened at $53.85 on Friday. The stock has a market capitalization of $10.34 billion, a P/E ratio of 15.98, a P/E/G ratio of 0.69 and a beta of 0.33. BioMarin Pharmaceutical has a 12-month low of $52.47 and a 12-month high of $73.51. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.56 and a quick ratio of 3.60. The firm's 50-day moving average is $56.48 and its two-hundred day moving average is $58.32.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. lifted its stake in shares of BioMarin Pharmaceutical by 212.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company's stock valued at $112,607,000 after purchasing an additional 1,083,512 shares in the last quarter. Covea Finance raised its holdings in BioMarin Pharmaceutical by 27.3% in the second quarter. Covea Finance now owns 135,300 shares of the biotechnology company's stock valued at $7,437,000 after buying an additional 29,000 shares during the period. GAMMA Investing LLC raised its holdings in BioMarin Pharmaceutical by 154.0% in the first quarter. GAMMA Investing LLC now owns 3,129 shares of the biotechnology company's stock valued at $221,000 after buying an additional 1,897 shares during the period. Robeco Institutional Asset Management B.V. lifted its position in BioMarin Pharmaceutical by 12.3% during the first quarter. Robeco Institutional Asset Management B.V. now owns 97,261 shares of the biotechnology company's stock valued at $6,875,000 after buying an additional 10,687 shares in the last quarter. Finally, Tealwood Asset Management Inc. grew its stake in BioMarin Pharmaceutical by 37.4% during the second quarter. Tealwood Asset Management Inc. now owns 21,563 shares of the biotechnology company's stock worth $1,185,000 after buying an additional 5,874 shares during the period. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.